...
首页> 外文期刊>Antimicrobial Resistance and Infection Control >Risk for subsequent infection and mortality after hospitalization among patients with multidrug-resistant gram-negative bacteria colonization or infection
【24h】

Risk for subsequent infection and mortality after hospitalization among patients with multidrug-resistant gram-negative bacteria colonization or infection

机译:具有多重耐药性革兰氏阴性菌定植或感染的患者住院后继发感染和死亡的风险

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Risks for subsequent multidrug-resistant gram-negative bacteria (MDRGNB) infection and long-term outcome after hospitalization among patients with MDRGNB colonization remain unknown. This observational study enrolled 817 patients who were hospitalized in the study hospital in 2009. We defined MDRGNB as a GNB resistant to at least three different antimicrobial classes. Patients were classified into MDRGNB culture-positive (MDRGNB-CP; 125 patients) and culture-negative (MDRGNB-CN; 692 patients) groups based on the presence or absence of any MDRGNB identified from either active surveillance or clinical cultures during index hospitalization. Subsequent MDRGNB infection and mortality within 12?months after index hospitalization were recorded. We determined the frequency and risk factors for subsequent MDRGNB infection and mortality associated with previous MDRGNB culture status. In total, 129 patients had at least one subsequent MDRGNB infection (MDRGNB-CP, 48.0%; MDRGNB-CN, 10.0%), and 148 patients died (MDRGNB-CP, 31.2%; MDRGNB-CN, 15.9%) during the follow-up period. MDR Escherichia coli and Acinetobacter baumannii were the predominant colonization microorganisms; patients with Proteus mirabilis and Pseudomonas aeruginosa had the highest hazard risk for developing subsequent infection. After controlling for other confounders, MDRGNB-CP during hospitalization independently predicted subsequent MDRGNB infection (hazard ratio [HR], 5.35; 95% confidence interval [CI], 3.72–7.71), all-cause mortality (HR, 2.42; 95% CI, 1.67–3.50), and subsequent MDRGNB infection-associated mortality (HR, 4.88; 95% CI, 2.79–8.52) after hospitalization. Harboring MDRGNB significantly increases patients’ risk for subsequent MDRGNB infection and mortality after hospitalization, justifying the urgent need for developing effective strategies to prevent and eradicate MDRGNB colonization.
机译:MDRGNB定植患者中随后发生多重耐药性革兰氏阴性菌(MDRGNB)感染的风险以及住院后长期预后的风险仍然未知。这项观察性研究招募了817位于2009年在研究医院住院的患者。我们将MDRGNB定义为对至少三种不同抗菌药物耐药的GNB。根据在住院期间从主动监测或临床培养中鉴定出的任何MDRGNB的存在与否,将患者分为MDRGNB培养阳性(MDRGNB-CP; 125例)和培养阴性(MDRGNB-CN; 692例)组。记录指数住院后12个月内的随后MDRGNB感染和死亡率。我们确定了随后的MDRGNB感染的频率和危险因素以及与先前MDRGNB培养状态相关的死亡率。在随后的随访中,共有129例患者至少发生了一次MDRGNB感染(MDRGNB-CP,48.0%; MDRGNB-CN,10.0%),并且有148例患者死亡(MDRGNB-CP,31.2%; MDRGNB-CN,15.9%)。上升期。耐多药大肠杆菌和鲍曼不动杆菌是主要的定殖微生物。变形杆菌和铜绿假单胞菌患者发生随后感染的危险性最高。在控制了其他混杂因素后,住院期间的MDRGNB-CP独立预测了随后的MDRGNB感染(危险比[HR],5.35; 95%置信区间[CI],3.72-7.71),全因死亡率(HR,2.42; 95%CI (1.67–3.50),以及随后住院后与MDRGNB感染相关的死亡率(HR,4.88; 95%CI,2.79–8.52)。携带MDRGNB会大大增加患者住院后继发MDRGNB感染和死亡的风险,这迫切需要制定预防和根除MDRGNB定植的有效策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号